Education
About Us
Working with TipRanks
Follow Us
D.Western Therapeutics Institute, Inc. (DE:6DW)
FRANKFURT:6DW
6DW Stock Chart & Stats
€0.47
-€0.01(-1.06%)
At close: 4:00 PM EST
€0.47
-€0.01(-1.06%)
Day’s Range― - ―
52-Week Range€0.40 - €1.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€31.10M
Enterprise Value€3.25B
Total Cash (Recent Filing)€1.05B
Total Debt (Recent Filing)€517.95M
Price to Earnings (P/E)―
Beta-0.89
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding54,251,713
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.21
Price to Sales (P/S)11.87
P/FCF Ratio-9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageA materially lower debt-to-equity in 2025 versus 2024 reduces near-term refinancing risk and interest burden, improving financial flexibility. This stronger leverage profile supports multi-month runway for R&D and operations and lowers the probability of urgent capital raises over the medium term.
High Gross MarginsSustainably high gross margins signal favorable unit economics for products or services, meaning revenue growth can flow through to operating leverage once fixed costs are controlled. This structural margin advantage supports long-term profitability potential if operating losses are reduced.
Narrowing Cash BurnA material reduction in cash burn year-over-year indicates management progress in cost control and operational efficiency. If the trend persists, it extends runway, reduces reliance on external financings, and increases the chance of reaching break-even within a multi-quarter horizon.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow prevents self-funding of operations and product development, forcing dependence on external capital. Over the medium term this raises dilution and refinancing risk and can constrain strategic investments and commercialization plans.
Small, Volatile RevenueLow and inconsistent revenue undermines predictable cash generation and makes scaling uncertain. Volatility complicates budgeting for R&D and commercialization, slows margin expansion, and increases the likelihood that future growth will require significant incremental investment or successful pipeline milestones.
Net Losses Exceed RevenueDeep net losses relative to revenue indicate the company is far from profitability and erode returns on equity. Sustained large losses will continue to deplete cash and equity unless reversed, making long-term viability contingent on either rapid revenue ramp or substantial external funding.
D.Western Therapeutics Institute News
6DW FAQ
What was D.Western Therapeutics Institute, Inc.’s price range in the past 12 months?
D.Western Therapeutics Institute, Inc. lowest stock price was €0.40 and its highest was €1.06 in the past 12 months.
What is D.Western Therapeutics Institute, Inc.’s market cap?
D.Western Therapeutics Institute, Inc.’s market cap is €31.10M.
When is D.Western Therapeutics Institute, Inc.’s upcoming earnings report date?
D.Western Therapeutics Institute, Inc.’s upcoming earnings report date is May 07, 2026 which is in 78 days.
How were D.Western Therapeutics Institute, Inc.’s earnings last quarter?
D.Western Therapeutics Institute, Inc. released its earnings results on Feb 13, 2026. The company reported -€0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.013.
Is D.Western Therapeutics Institute, Inc. overvalued?
According to Wall Street analysts D.Western Therapeutics Institute, Inc.’s price is currently Overvalued.
Does D.Western Therapeutics Institute, Inc. pay dividends?
D.Western Therapeutics Institute, Inc. does not currently pay dividends.
What is D.Western Therapeutics Institute, Inc.’s EPS estimate?
D.Western Therapeutics Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute, Inc. have?
D.Western Therapeutics Institute, Inc. has 54,251,713 shares outstanding.
What happened to D.Western Therapeutics Institute, Inc.’s price movement after its last earnings report?
D.Western Therapeutics Institute, Inc. reported an EPS of -€0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.804%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute, Inc.?
Currently, no hedge funds are holding shares in DE:6DW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
D.Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Technical Analysis
OncoTherapy Science
―
Immuno-Biological Laboratories Co., Ltd.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―
Kringle Pharma, Inc.
―